Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

Background Abiraterone acetate plus prednisone or prednisolone improves progression-
free survival and overall survival in patients with metastatic castration-resistant prostate …

Importance Targeted alpha therapy attempts to deliver systemic radiation selectively to
cancer cells while minimizing systemic toxic effects and may lead to additional treatment …

Abstract Purpose: Radium-223 dichloride (radium-223, Xofigo), a targeted alpha therapy, is
currently used for the treatment of patients with castration-resistant prostate cancer (CRPC) …

Metastatic prostate cancer patients present in two ways—with already disseminated disease
at the time of presentation or with disease recurrence after definitive local therapy. Androgen …

The introduction of novel therapeutic agents for advanced prostate cancer has led to a wide
range of treatment options for patients with metastatic castration-resistant prostate cancer …

Abstract Radium Ra-223 dichloride (radium-223, Xofigo®) is a targeted alpha therapy
approved for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic …

α-Emitting radionuclides have been approved for cancer treatment since 2013, with
increasing degrees of success. Despite this clinical utility, little is known regarding the …

Targeted radionuclide therapy (TRT) is a branch of cancer medicine concerned with the use
of radioisotopes, radiolabelled molecules, nanoparticles, or microparticles that either …